Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tianhui Chen is active.

Publication


Featured researches published by Tianhui Chen.


Cancer Letters | 2016

National estimates of cancer prevalence in China, 2011.

Rongshou Zheng; Hongmei Zeng; Siwei Zhang; Tianhui Chen; Wanqing Chen

OBJECTIVE Little is known about the nationwide cancer prevalence in China. This paper aimed at assessing the 5-year cancer prevalence in China for 25 major cancers. MATERIALS AND METHODS Incidence data were estimated using data from 177 cancer registries and covering 175 million populations. Survival data were from 17 cancer registries diagnosed during 2003-2005 and followed up until 31 December 2010. Standardized protocols for data collection and validation were adopted. Cancer prevalence for 25 major sites was estimated from year-specific incidence rates and survival probabilities according to standardized formula. RESULTS The estimated 5-year prevalence for all cancers combined in 2011 in China was 7.49 million (3.68 million for men and 3.81 million for women). Cancer prevalence estimates for 5 years varied by cancer sites, ranging from 11,900 for testicular cancer to 1.02 million for women breast cancer. Those most prevalent five cancers (breast, colorectal, lung, stomach and esophageal cancers) covered 56.1% of cancer burden in China. The proportion for the 5-year prevalence was higher in urban areas compared to rural areas (666 per 100,000 versus 440 per 100,000), while cancer prevalence estimates were higher for women compared to men, with the men/women ratio of 5-year cancer prevalence reaching 0.96. CONCLUSIONS This paper provides the first systematic analysis on 5-year cancer prevalence for 25 major cancers in China in 2011, which may serve as a baseline for assessment of the overall effectiveness of cancer health care. The huge number of cancer survivors requires resource allocation to improve health care programs and primary prevention, especially in rural areas.


Obstetrics & Gynecology | 2011

Determinants of maternal sex steroids during the first half of pregnancy.

Adetunji T. Toriola; Marja Vääräsmäki; Matti Lehtinen; Anne Zeleniuch-Jacquotte; Eva Lundin; Kenneth-Gary Rodgers; Hans-Åke Lakso; Tianhui Chen; Helena Schock; Göran Hallmans; Eero Pukkala; Paolo Toniolo; Kjell Grankvist; Heljä-Marja Surcel; Annekatrin Lukanova

OBJECTIVE: To examine the associations of maternal and child characteristics with early pregnancy maternal concentrations of testosterone, androstenedione, progesterone, 17-hydroxyprogesterone, and estradiol (E2). METHODS: We analyzed these hormones among 1,343 women with singleton pregnancies who donated serum samples to the Finnish Maternity Cohort from 1986 to 2006 during the first half of pregnancy (median 11 weeks). The associations of maternal and child characteristics with hormone concentrations were investigated by correlation and multivariable regression. RESULTS: Women older than age 30 years had lower androgen and E2 but higher progesterone concentrations than women younger than that age. Multiparous women had 14% lower testosterone, 11% lower androstenedione and 17-hydroxyprogesterone, 9% lower progesterone, and 16% lower E2 concentrations compared with nulliparous women (all P<.05). Smoking mothers had 11%, 18%, and 8% higher testosterone, androstenedione, and 17-hydroxyprogesterone levels, respectively, but 10% lower progesterone compared with nonsmoking women (all P<.05). E2 concentrations were 9% higher (P<.05) among women with a female fetus compared with those with a male fetus. CONCLUSION: Parity, smoking, and, to a lesser extent, maternal age and child sex are associated with sex steroid levels during the first half of a singleton pregnancy. The effects of smoking on the maternal hormonal environment and the possible long-term deleterious consequences on the fetus deserve further evaluation. LEVEL OF EVIDENCE: II


Cancer Research | 2010

Human Chorionic Gonadotropin in Pregnancy and Maternal Risk of Breast Cancer

Paolo Toniolo; Kjell Grankvist; Marianne Wulff; Tianhui Chen; Robert Johansson; Helena Schock; Per Lenner; Göran Hallmans; Matti Lehtinen; Rudolf Kaaks; Göran Wadell; Anne Zeleniuch-Jacquotte; Eva Lundin; Annekatrin Lukanova

Full-term pregnancies are associated with long-term reductions in maternal risk of breast cancer, but the biological determinants of the protection are unknown. Experimental observations suggest that human chorionic gonadotropin (hCG), a major hormone of pregnancy, could play a role in this association. A case-control study (242 cases and 450 controls) nested within the Northern Sweden Maternity Cohort included women who had donated a blood sample during the first trimester of a first full-term pregnancy. Total hCG was determined on Immulite 2000 analyzer. Odds ratios (OR) and 95% confidence intervals (CI) were estimated through conditional logistic regression. Maternal breast cancer risk decreased with increasing hCG (upper tertile OR, 0.67; CI, 0.46-0.99), especially for pregnancies before age 25 (upper tertile OR, 0.41; CI, 0.21-0.80). The association diverged according to age at diagnosis: risk was reduced after age 40 (upper tertile OR, 0.60; CI, 0.39-0.91) and seemed to increase before age 40 (upper tertile OR, 1.78; CI, 0.72-4.38). Risk was reduced among those diagnosed 10 years or longer after blood draw (upper tertile OR, 0.60; CI, 0.40-0.90), but not so among those diagnosed within 10 years (upper tertile OR, 4.33; CI, 0.86-21.7). These observations suggest that the association between pregnancy hCG and subsequent maternal risk of breast cancer is modified by age at diagnosis. Although the hormone seems to be a determinant of the reduced risk around or after age 50, it might not confer protection against, or it could even increase the risk of, cancers diagnosed in the years immediately following pregnancy.


Cancer Causes & Control | 2010

Maternal hormones during early pregnancy: a cross-sectional study

Tianhui Chen; Eva Lundin; Kjell Grankvist; Anne Zeleniuch-Jacquotte; Marianne Wulff; Yelena Afanasyeva; Helena Schock; Robert Johansson; Per Lenner; Göran Hallmans; Göran Wadell; Paolo Toniolo; Annekatrin Lukanova

BackgroundLittle is known about correlates of first-trimester pregnancy hormones as in most studies maternal hormones have been measured later in gestation. We examined the associations of maternal characteristics and child sex with first-trimester maternal concentrations of four hormones implicated in breast cancer: human chorionic gonadotropin (hCG), α-fetoprotein (AFP), insulin-like growth factor (IGF)-I, and IGF-II.MethodsAbout 338 serum samples donated to the Northern Sweden Maternity Cohort (NSMC), 1975–2001, during the first trimester of uncomplicated pregnancies, were analyzed for the hormones of interest as a part of a case–control study. The associations of maternal characteristics and child sex with hormone concentrations were investigated by correlation, general linear regression, and multivariate regression models.ResultsIn the first trimester, greater maternal age was inversely correlated with IGF-I and IGF-II. In comparison with women carrying their first child, already parous women had higher IGF-I but lower hCG. Greater maternal weight and smoking were inversely correlated with hCG. No differences in hormone levels by child sex were observed.ConclusionsOur analyses indicated that potentially modifiable maternal characteristics (maternal weight and smoking) influence first-trimester pregnancy maternal hormone concentrations.


Cancer Epidemiology, Biomarkers & Prevention | 2011

Circulating Sex Steroids during Pregnancy and Maternal Risk of Non-epithelial Ovarian Cancer

Tianhui Chen; Helja Marja Surcel; Eva Lundin; Marjo Kaasila; Hans-Åke Lakso; Helena Schock; Rudolf Kaaks; Pentti Koskela; Kjell Grankvist; Göran Hallmans; Eero Pukkala; Anne Zeleniuch-Jacquotte; Paolo Toniolo; Matti Lehtinen; Annekatrin Lukanova

Background: Sex steroid hormones have been proposed to play a role in the development of non-epithelial ovarian cancers (NEOC) but so far no direct epidemiologic data are available. Methods: A case–control study was nested within the Finnish Maternity Cohort, the worlds largest biorepository of serum specimens from pregnant women. Study subjects were selected among women who donated a blood sample during a singleton pregnancy that led to the birth of their last child preceding diagnosis of NEOC. Case subjects were 41 women with sex cord stromal tumors (SCST) and 21 with germ cell tumors (GCT). Three controls, matching the index case for age, parity at the index pregnancy, and date at blood donation were selected (n = 171). OR and 95% CI associated with concentrations of testosterone, androstenedione, 17-OH-progesterone, progesterone, estradiol, and sex hormone–binding globulin (SHBG) were estimated through conditional logistic regression. Results: For SCST, doubling of testosterone, androstenedione, and 17-OH-progesterone concentrations were associated with about 2-fold higher risk of SCST [ORs and 95% CI of 2.16 (1.25–3.74), 2.16 (1.20–3.87), and 2.62 (1.27–5.38), respectively]. These associations remained largely unchanged after excluding women within 2-, 4-, or 6-year lag time between blood donation and cancer diagnosis. Sex steroid hormones concentrations were not related to maternal risk of GCT. Conclusions: This is the first prospective study providing initial evidence that elevated androgens play a role in the pathogenesis of SCST. Impact: Our study may note a particular need for larger confirmatory investigations on sex steroids and NEOC. Cancer Epidemiol Biomarkers Prev; 20(2); 324–36. ©2010 AACR.


Cancer Letters | 2015

Incidence, mortality and survival of childhood cancer in China during 2000-2010 period: A population-based study

Rongshou Zheng; Xiaoxia Peng; Hongmei Zeng; Siwei Zhang; Tianhui Chen; Huanmin Wang; Wanqing Chen

The objective of this study is to assess Chinese nationwide incidence, mortality and survival of childhood cancers, which has not been reported. Data from 145 Chinese Cancer Registries, which covered 158,403,248 populations, were pooled for analyses. Cancer patients were diagnosed during 2000-2010 at age 0-14 years. Age-standardized incidence and mortality rates and relative survival rates were calculated. Survival was estimated by the classic cohort approach. New cancer cases were projected using a Bayesian age-period-cohort model. Overall age-standardized incidence was 87.1 per million and age-standardized mortality was 36.3 per million. We found a statistically significant increase in incidence rate annually with 2.8% (95% CI: 1.1-4.6%, p < 0.05), a non-significant decreased mortality, and overall 5-year relative survival reaching 71.9% (95% CI: 69.4-77.1%). Projected new cases in 2015 are 22,875. We provide, for the first time, Chinese nationwide incidence, mortality and their temporal trends, and relative survival rates during the period of 2003-2005 for childhood cancer, which will contribute to a better understanding of the etiology and prevention of childhood cancers. The increasing trend of incidence rate and low 5-year relative survival rate suggest that more efforts for prevention and control of childhood cancers shall be invested in China.


Cancer Letters | 2015

Distribution and risk of the second discordant primary cancers combined after a specific first primary cancer in German and Swedish cancer registries.

Tianhui Chen; Mahdi Fallah; Lina Jansen; Felipe A. Castro; Agne Krilavicuite; Alexander Katalinic; Nora Eisemann; Katharina Emrich; Bernd Holleczek; Karla Geiss; Andrea Eberle; Jan Sundquist; Hermann Brenner; Kari Hemminki

We aimed at investigating the distribution and risk of all second discordant primary cancers (SDPCs) after a specific first primary cancer in Germany and Sweden to provide etiological understanding of SDPCs and insight into their incidence rates and recording practices. Among 1,537,004 survivors of first primary cancers in Germany and 588,103 in Sweden, overall 80,162 and 32,544 SDPCs were recorded, respectively. Standardized incidence ratios (SIRs) of all SDPCs were elevated at levels between 1.1 and 2.1 after 23 (out of overall 29) cancers in Germany and at levels between 1.1 and 1.6 after 24 cancers in Sweden, and among them, elevated SIRs were found after 19 cancers in both populations. Decreased SIRs at levels ranging from 0.5 to 0.9 were found for some cancers with poor prognosis in Germany only. We found elevated risk after 19 out of 29 cancers in both countries, suggesting common etiology of SDPCs after most of first cancers and registration similarity. Decreased risks after some fatal cancers were found only in Germany, which may be attributed to reporting practices or missed death data in Germany.


Cancer Epidemiology, Biomarkers & Prevention | 2011

Circulating Insulin-like Growth Factor-I in Pregnancy and Maternal Risk of Breast Cancer

Adetunji T. Toriola; Eva Lundin; Helena Schock; Kjell Grankvist; Eero Pukkala; Tianhui Chen; Anne Zeleniuch-Jacquotte; Paolo Toniolo; Matti Lehtinen; Heljä-Marja Surcel; Annekatrin Lukanova

Background: Elevated serum concentrations of insulin-like growth factor (IGF)-I have been associated with increased risk of developing breast cancer. Previously, we reported a similar association in samples obtained during pregnancy. This study was conducted to further characterize the association of IGF-I during pregnancy with maternal breast cancer risk. Methods: A case–control study was nested within the Finnish Maternity Cohort. The study was limited to primiparous women younger than 40 years, who donated blood samples during early (median, 12 weeks) pregnancy and delivered a single child at term. Seven hundred nineteen women with invasive breast cancer were eligible. Two controls (n = 1,434) were matched with each case on age and date at blood donation. Serum IGF-I concentration was measured using an Immulite 2000 analyzer. Conditional logistic regression was used to estimate ORs and 95% CIs. Results: No significant associations were observed between serum IGF-I concentrations and breast cancer risk in both the overall analysis (OR, 1.08; 95% CI, 0.80–1.47) and in analyses stratified by histologic subtype, lag time to cancer diagnosis, age at pregnancy, or age at diagnosis. Conclusion: There was no association between IGF-I and maternal breast cancer risk during early pregnancy in this large nested case–control study. Impact: Serum IGF-I concentrations during early pregnancy may not be related to maternal risk of developing breast cancer. Cancer Epidemiol Biomarkers Prev; 20(8); 1798–801. ©2011 AACR.


Journal of Epidemiology | 2016

Risk Factors for Pancreatic Cancer in China: A Multicenter Case-Control Study.

Zhaoxu Zheng; Rongshou Zheng; Yutong He; Xibin Sun; Ning Wang; Tianhui Chen; Wanqing Chen

Background Despite having one of the highest mortality rates of all cancers, the risk factors of pancreatic cancer remain unclear. We assessed risk factors of pancreatic cancer in China. Methods A case-control study design was conducted using data from four hospital-based cancer registries (Henan Provincial Cancer Hospital, Beijing Cancer Hospital, Hebei Provincial Cancer Hospital, and Cancer Hospital of Chinese Academy of Medical Sciences). Controls were equally matched and selected from family members of non-pancreatic cancer patients in the same hospitals. Face-to-face interviews were conducted by trained staff using questionnaires. Conditional logistic regression models were used to assess odd ratios (ORs) and 95% confident intervals (CIs). Results Among 646 recruited participants, 323 were pancreatic cancer patients and 323 were controls. Multivariate logistic analysis suggested that pancreatic cancer family history (adjusted OR 1.23; 95% CI, 1.11–3.70), obesity (adjusted OR 1.77; 95% CI, 1.22–2.57), diabetes (adjusted OR 2.96; 95% CI, 1.48–5.92) and smoking (adjusted OR 1.78; 95% CI, 1.02–3.10) were risk factors for pancreatic cancer, but that drinking tea (adjusted OR 0.49; 95% CI, 0.25–0.84) was associated with reduced risk of pancreatic cancer. Conclusions Cigarette smoking, family history, obesity, and diabetes are risk factors of pancreatic cancer, which is important information for designing early intervention and preventive strategies for pancreatic cancer and may be beneficial to pancreatic cancer control in China.


Scientific Reports | 2016

Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries.

Tianhui Chen; Mahdi Fallah; Hermann Brenner; Lina Jansen; Elias K. Mai; Felipe A. Castro; Alexander Katalinic; Katharina Emrich; Bernd Holleczek; Karla Geiss; Andrea Eberle; Kristina Sundquist; Kari Hemminki

We aimed at investigating the distribution and risk of second primary cancers (SPCs) in multiple myeloma (MM) survivors in Germany and Sweden to provide etiological understanding of SPCs and insight into their incidence rates and recording practices. MM patients diagnosed in 1997–2010 at age ≥15 years were selected from the Swedish (nationwide) and 12 German cancer registries. Standardized incidence ratios (SIRs) were used to assess risk of a specific SPC compared to risk of the same first cancer in the corresponding background population. Among 18,735 survivors of first MM in Germany and 7,560 in Sweden, overall 752 and 349 SPCs were recorded, respectively. Significantly elevated SIRs of specific SPCs were observed for acute myeloid leukemia (AML; SIR = 4.9) in Germany and for kidney cancer (2.3), AML (2.3) and nervous system cancer (1.9) in Sweden. Elevated risk for AML was more pronounced in the earlier diagnosis period compared to the later, i.e., 9.7 (4.2–19) for 1997–2003 period versus 3.5 (1.5–6.9) for 2004–2010 in Germany; 3.8 (1.4–8.3) for 1997–2003 versus 2.2 (0.3–7.8) for 2004–2010 in Sweden. We found elevated risk for AML for overall, early diagnosis periods and longer follow-up times in both populations, suggesting possible side effects of treatment for MM patients.

Collaboration


Dive into the Tianhui Chen's collaboration.

Top Co-Authors

Avatar

Helena Schock

German Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge